Considering that oncogenic activation of the EGFR pathway results in an immune-inert phenotype and recent literature has implicated a potential role of YY1 in mediating tumor immune escape [36, 43–46], these conclusions may also be tentatively extrapolated to cancer immunotherapy. The gene discussed is YY1; the disease is cancer.